Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 446 participants.
Also called NCT06347003
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 446 participants
- Sponsor
- Registry
-
NCT06347003 -
2023-509300-14
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Croatia, Czechia, Hungary, Italy, Poland, Romania, Slovakia, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT06347003. Randomized; quadruple masking; primary purpose treatment. Start 2024-07-22 (actual); primary completion 2026-06-12 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
- Acronym
- SHASTA-3
- Condition
- Severe Hypertriglyceridemia
- Intervention (Drug)
- Plozasiran Injection
- Intervention (Drug)
- Placebo
- Lead sponsor
- Arrowhead Pharmaceuticals
Record details
- Record id
cardio:ct-nct06347003- Content hash
1910cf8efdc5dc8bc9cb3aad3b6dcfb4c0df32ce704f974077a0a786f3ff32c4